Converted by EDGARwiz

NOVOGEN LIMITED

(ASX: NRT)

[asxreleasenovogen20131021002.gif]

ASX RELEASE

21 October 2013

Purchase of Convertible Security

Novogen today announced that it has under the Convertible Securities

Agreement referred to in its announcement of 4 July 2013, issued a second

convertible security to its US based institutional investor. This will raise

another $1 million to fund Novogen’s continued drug development program.

The terms of the Convertible Securities Agreement remain unchanged.

Dr Graham Kelly, Novogen CEO said. “We recently announced the acquisition

of a second drug technology platform known as anti-tropomyosins. The funds

raised through the issuance of this convertible security will be applied to the

development of that drug platform.”

About Novogen

Novogen Ltd is a public Australia biotechnology company whose shares trade

on both the Australia Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol

‘NVGN’). The company is based in Sydney, Australia, with an office in Ithaca,

NY, USA. The Company is focused on the development of drug strategies

that will deliver personalized chemotherapy based on the effective elimination

of cancer stem cells and somatic cancer cells across a range of genotypes.

Yours truly,

Lionel Mateo

Company Secretary

NOVOGEN LTD – ACN 063 259 754

16-20 Edgeworth David Ave, Hornsby, NSW, 2077

P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388